Ophthalmic complications of immune checkpoint inhibitors

References

• Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers (Basel). 2020;12:738. doi:https://doi.org/10.3390/cancers12030738.
   PubMed Web of Science ®Google Scholar
• Wladis EJ, Lee JA, Martino N, Adam AP. Programmed death-1 pathway in orbital invasion of cutaneous carcinomas. Ophthalmic Plast Reconstr Surg. 2018;34:110–113. doi:https://doi.org/10.1097/IOP.0000000000000880.
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, Oweira H, Petrausch U, Helbing D, Schmidt J, Mannhart M, et al. Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review. Expert Rev Anticancer Ther. 2017;4:387–394. doi:https://doi.org/10.1080/14737140.2017.1296765.
   Google Scholar
• Kim YJ, Lee JS, Lee J, Lee SC, Kim T-I, Byeon SH, et al. Factors associated with ocular adverse event after immune checkpoint inhibitor treatment. Cancer Immunol Imunotherapy. 2020. epub ahead of print. doi:https://doi.org/10.1007/s00262-020-02635-3.
   Google Scholar
• Noble CW, Gangaputra SS, Thompson IA, Yuan A, Apolo AB, Lee J-M, et al. Ocular adverse events following use of immune checkpoint inhibitors for metastatic malignancies. Ocul Immunol Inflamm. 2020;28(6):854–859.
   PubMed Web of Science ®Google Scholar
• Dalvin LA, Shields CL, Orloff M, Sato T, Shields JA. Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects. Retina. 2018;38:1063–1078. doi:https://doi.org/10.1097/IAE.0000000000002181.
   PubMed Web of Science ®Google Scholar
• Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017;35(7):785–792. doi:https://doi.org/10.1200/JCO.2015.66.1389.
   PubMed Web of Science ®Google Scholar
• Bitton K, Michot JM, Barreau E, Lambotte O, Haigh O, Marabelle A, et al. Prevalence and clinical patterns of ocular complications associated with anti-PD-1/PD-L1 anticancer immunotherapy. Am J Ophthalmol. 2019;202:109–117. doi:https://doi.org/10.1016/j.ajo.2019.02.012.
   PubMed Web of Science ®Google Scholar
• Parikh RA, Chaon BC, Berkenstock MK. Ocular complications of checkpoint inhibitors and immunotherapeutic agents: a case series. Ocul Immunol Inflamm. 2020. doi:https://doi.org/10.1080/09273948.2020.1766082.
   Google Scholar
• Fang T, Maberley DA, Etminan M. Ocular adverse events with immune checkpoint inhibitors. J Curr Ophthalmol. 2019;31:319–322. doi:https://doi.org/10.1016/j.joco.2019.05.002.
   PubMed Web of Science ®Google Scholar
• Abu Samra K, Valdes-Navarro M, Lee S, Swan R, Foster CS, Anesi SD, et al. A case of bilateral uveitis and papillitis in a patient treated with pembrolizumab. Eur J Ophthalmol. 2016;26:e46–e48. doi:https://doi.org/10.5301/ejo.5000724.
   PubMed Web of Science ®Google Scholar
• Reddy M, Chen JJ, Kalevar A, Terribilini R, Agarwal A. Immune retinopathy associated with nivolumab administration for metastatic non-small cell lung cancer. Retinal Cases Brief Rep. 2020;14:120–126. doi:https://doi.org/10.1097/ICB.0000000000000675.
   PubMedGoogle Scholar
• Miyamoto R, Nakashizuka H, Tanaka K, Wakatsuki Y, Onoe H, Mori R, et al. Bilateral multiple serous retinal detachments after treatment with nivolumab: a case report. BMC Ophthalmol. 2020;20:221. doi:https://doi.org/10.1186/s12886-020-01495-w.
   PubMed Web of Science ®Google Scholar
• Mantopoulos D, Kendra KL, Letson AD, Cebulla CM. Bilateral choroidopathy and serious retinal detachments during ipilmumab treatment for cutaneous melanoma. JAMA Ophthalmol. 2015;133:965–967. doi:https://doi.org/10.1001/jamaophthalmol.2015.1128.
   PubMed Web of Science ®Google Scholar
• Crew J, Agarwal A, Jack L, Xu D, Do DV, Nguyen QD, et al. Ipilimumab-associated retinopathy. Ophthalmic Surg Lasers Imaging Retina. 2015;46:658–660. doi:https://doi.org/10.3928/23258160-20150610-10.
   PubMed Web of Science ®Google Scholar
• Thomas M, Armenti ST, Ayres MB, Demicri H. Uveal effusion after immune checkpoint inhibitor therapy. JAMA Ophthalmol. 2018;136(5):553–556. doi:https://doi.org/10.1001/jamaophthalmol.2018.0920.
   PubMed Web of Science ®Google Scholar
• Modjthahedi BS, Maibach H, Park S. Multifocal bilateral choroidal neovascularization in a patient on ipilimumab for metastatic melanoma. Cutan Ocul Toxicol. 2013;32:341–343. doi:https://doi.org/10.3109/15569527.2013.781618.
   PubMed Web of Science ®Google Scholar
• Lise Q-K, Audrey A-G. Mutifocal choroiditis as the first sign of systemic sarcoidosis associated with pembrolizumab. Am J Ophthalmol Case Rep. 2017;5:92–93. doi:https://doi.org/10.1016/j.ajoc.2016.12.014.
   PubMedGoogle Scholar
• Ung C, Gragoudas E. Checkpoint inhibitor-induced sarcoid choroidal granulomas. Am J Ophthalmol Case Rep. 2020;18:100652. doi:https://doi.org/10.1016/j.ajoc.2020.100652.
   PubMedGoogle Scholar
• Nguyen M, Islam MR, Lim SW, Sahu A, Tamjid B. Pembrolizumab induced ocular hypotony with near complete vision loss, interstitial pulmonary fibrosis, and arthritis. Front Oncol. 2019;9:944. doi:https://doi.org/10.3389/fonc.2019.00944.
   PubMed Web of Science ®Google Scholar
• Antoun J, Titah C, Cochereau I. Ocular and orbital side effects of checkpoint inhibitors: a review article. Curr Opin Oncol. 2016;28:288–294. doi:https://doi.org/10.1097/CCO.0000000000000296.
   PubMed Web of Science ®Google Scholar
• Lorenzo CJ, Fitzpatrick H, Campdesuner V, George J, Lattanzio N. Pembrolizumab-induced ocular myasthenic crisis. Cureus. 2020;12(7):e9192. doi:https://doi.org/10.7759/cureus.9192.
   PubMed Web of Science ®Google Scholar
• Jeyakumar N, Etchegaray M, Henry J, Lelenwa L, Zhao B, Segura A, et al. The terrible triad of checkpoint inhibition: a case report of myasthenia gravis, myocarditis, and myositis induced by cemiplimab in a patient with metastatic cutaneous squamous cell carcinoma. Case Reports Immunol. 2020;2020:5126717. doi:https://doi.org/10.1155/2020/5126717.
   PubMed Web of Science ®Google Scholar
• Liu Q, Ayyappan S, Broad A, Narita A. Pembrolizumab-associated ocular myasthenia gravis. Clin Exp Ophthalmol. 2019;47:796–798. doi:https://doi.org/10.1111/ceo.13499.
   PubMed Web of Science ®Google Scholar
• Kamo H, Hatano T, Kanai K, Aoki N, Kamiyama D, Yokoyama K, et al. Pembrolizumab-related systemic myositis involving ocular and hindneck muscles resembling myasthenia gravis: a case report. BMC Neurol. 2019;19:184. doi:https://doi.org/10.1186/s12883-019-1416-1.
   PubMed Web of Science ®Google Scholar
• Garibaldi M, Calabro F, Merlonghi G, Pugliese S, Ceccanti M, Cristiano L, et al. Immune checkpoint inhibitors (ICIs)-related ocular myositis. Neuromuscular Disord. 2020;30:420–423. doi:https://doi.org/10.1016/j.nmd.2020.02.013.
   PubMed Web of Science ®Google Scholar
• Goldstein BL, Gedmintas L, Todd DJ. Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of CTLA-4. Arthritis Rheumatol. 2014;66:768–769. doi:https://doi.org/10.1002/art.38282.
   PubMed Web of Science ®Google Scholar
• Ediriwickrema LS, Liu CY, Kikkawa DO, Korn BS. Development of poliosis following checkpoint inhibitor treatment for cutaneous melanoma. Ophthal Plast Reconstr Surg. 2019;35:e121–e122. doi:https://doi.org/10.1097/IOP.0000000000001451.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Lacchetti C, Schenider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2018;36(17):1714–1768. doi:https://doi.org/10.1200/JCO.2017.77.6385.
   PubMed Web of Science ®Google Scholar